[go: up one dir, main page]

EP1282411A4 - Methode de traitement anticancereux - Google Patents

Methode de traitement anticancereux

Info

Publication number
EP1282411A4
EP1282411A4 EP01927380A EP01927380A EP1282411A4 EP 1282411 A4 EP1282411 A4 EP 1282411A4 EP 01927380 A EP01927380 A EP 01927380A EP 01927380 A EP01927380 A EP 01927380A EP 1282411 A4 EP1282411 A4 EP 1282411A4
Authority
EP
European Patent Office
Prior art keywords
treatment method
anticancer treatment
anticancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01927380A
Other languages
German (de)
English (en)
Other versions
EP1282411A1 (fr
Inventor
Thomas P Kennedy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Charlotte Mecklenburg Hospital
Original Assignee
Charlotte Mecklenburg Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charlotte Mecklenburg Hospital filed Critical Charlotte Mecklenburg Hospital
Publication of EP1282411A1 publication Critical patent/EP1282411A1/fr
Publication of EP1282411A4 publication Critical patent/EP1282411A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01006—Catalase (1.11.1.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01009—Glutathione peroxidase (1.11.1.9)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP01927380A 2000-04-26 2001-03-02 Methode de traitement anticancereux Withdrawn EP1282411A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20002800P 2000-04-26 2000-04-26
US200028P 2000-04-26
PCT/US2001/040237 WO2001080849A1 (fr) 2000-04-26 2001-03-02 Methode de traitement anticancereux

Publications (2)

Publication Number Publication Date
EP1282411A1 EP1282411A1 (fr) 2003-02-12
EP1282411A4 true EP1282411A4 (fr) 2008-05-21

Family

ID=22740013

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01927380A Withdrawn EP1282411A4 (fr) 2000-04-26 2001-03-02 Methode de traitement anticancereux

Country Status (3)

Country Link
EP (1) EP1282411A4 (fr)
AU (1) AU2001253836A1 (fr)
WO (1) WO2001080849A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10160796A1 (de) * 2001-12-11 2003-06-26 Wulf Droege Verwendung einer Cystein-haltigen Substanz zur Steigerung der Atmungsaktivität und Erythropoetin-Produktion
WO2004026407A1 (fr) * 2002-09-06 2004-04-01 Institut Curie Utilisation d'inhibiteurs de composes impliques dans la voie metabolique cellulaire de la jun kinase (jnk) pour le traitement ou le diagnostic de liposarcomes
DE10337638A1 (de) * 2003-08-16 2005-03-24 Kirschfeld, Kuno, Prof. Dr. Verfahren zur Behandlung der Prostatitis
WO2006017211A1 (fr) * 2004-07-12 2006-02-16 Research Development Foundation Guggulsterone en tant qu'inhibiteur du facteur nucleaire kb et de l'activation de l'ikb kinase-alpha
WO2011091807A1 (fr) * 2010-01-31 2011-08-04 Abdelrahman Shata Mohammed Shata Anticoagulant et glutathion pour le traitement du cancer
CN102933216A (zh) 2010-04-28 2013-02-13 株式会社Ihi 抗脑瘤药物
JP5873656B2 (ja) * 2011-06-13 2016-03-01 株式会社Ihi 金属サレン錯体化合物、局所麻酔薬剤及び抗悪性腫瘍薬剤
EP3199152B1 (fr) 2014-09-26 2021-05-26 IHI Corporation Agent anticancéreux et procédé de destruction de cellules cancéreuses
JP2017128552A (ja) * 2016-01-22 2017-07-27 株式会社Ihi 抗癌剤、抗癌剤の制御方法
CN112121043A (zh) * 2020-10-27 2020-12-25 澳门大学 双香豆素在抗肿瘤中的应用
CN114558122B (zh) * 2022-04-27 2023-02-21 北京肿瘤医院(北京大学肿瘤医院) 放射核素标记的过氧化氢酶及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334382A (en) * 1993-02-25 1994-08-02 Sterling Winthrop Inc. Lyophilized polyethylene oxide modified catalase composition, polypeptide complexes with cyclodextrin and treatment of diseases with the catalase compositions
US5756091A (en) * 1993-04-22 1998-05-26 Cellfire Incorporated Method of treating tumour cells using catalase

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824664A (en) * 1993-03-26 1998-10-20 U.S. Bioscience, Inc. Suppression of HIV expression by organic thiophosphate
US5922757A (en) * 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334382A (en) * 1993-02-25 1994-08-02 Sterling Winthrop Inc. Lyophilized polyethylene oxide modified catalase composition, polypeptide complexes with cyclodextrin and treatment of diseases with the catalase compositions
US5756091A (en) * 1993-04-22 1998-05-26 Cellfire Incorporated Method of treating tumour cells using catalase

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRAR SUKHDEV S ET AL: "Reactive oxygen species from NAD(P)H:quinone oxidoreductase constitutively activate NF-kappaB in malignant melanoma cells", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 280, no. 3 Part 1, March 2001 (2001-03-01), pages C659 - C676, XP002475662, ISSN: 0002-9513 *
LIU TSAN-ZON ET AL: "Differentiation status modulates transcription factor NF-kappaB activity in unstimulated human hepatocellular carcinoma cell lines", CANCER LETTERS, vol. 151, no. 1, 3 April 2000 (2000-04-03), pages 49 - 56, XP002475661, ISSN: 0304-3835 *
SCHWARTZ S A ET AL: "The role of NF-[kappa]B/I[kappa]B proteins in cancer: Implications for novel treatment strategies", SURGICAL ONCOLOGY 1999 GB, vol. 8, no. 3, 1999, pages 143 - 153, XP002475660, ISSN: 0960-7404 *
See also references of WO0180849A1 *

Also Published As

Publication number Publication date
WO2001080849A1 (fr) 2001-11-01
AU2001253836A1 (en) 2001-11-07
EP1282411A1 (fr) 2003-02-12

Similar Documents

Publication Publication Date Title
DK1335678T3 (da) Oralt behandlingssystem
DE60142565D1 (de) Mittel zur wasserbehandlung
FR2814945B1 (fr) Procede de traitement de la canitie
KR100695846B9 (ko) 암 치료
DK1267650T3 (da) Tobakbehandling
NO20035156D0 (no) Fremgangsmåter for brönnbehandling
EP1446129A4 (fr) Therapie par polynucleotide
NL1014915A1 (nl) Nieuwe behandelingsmethode.
DE60217317D1 (de) Wärmebehandlungsverfahren
ATE350454T1 (de) Textilbehandlungsmittel
NO20032122D0 (no) Forbedret behandling
EP1485109A4 (fr) Traitement vasculaire
EP1282411A4 (fr) Methode de traitement anticancereux
DE60227963D1 (de) Behandlungssystem
PT102870A (pt) Metodo de tratamento de condensados
DE60220220D1 (de) Blutbehandlungssystem
NO20040087L (no) Fremgangsmate for behandling av sovnloshet
NO20013596D0 (no) Slambehandling
FI20012366L (fi) Jätevedenpuhdistamo
EP1553965A4 (fr) Methode de traitement des tumeurs
ATE250611T1 (de) Pyranoindole zur glaukombehandlung
DE60140597D1 (de) Vakuumbehandlungsverfahren
DE60125241D1 (de) Wärmebehandlungseinrichtung
ID30377A (id) Metoda pengobatan neurodegenerasi
FR2825893B3 (fr) Tunnel de traitement

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021122

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20080423

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20080414BHEP

Ipc: A61K 45/06 20060101ALI20080414BHEP

Ipc: A61K 31/44 20060101ALI20080414BHEP

Ipc: A61K 31/66 20060101ALI20080414BHEP

Ipc: A61K 31/452 20060101ALI20080414BHEP

Ipc: A61K 31/41 20060101ALI20080414BHEP

Ipc: A61K 31/37 20060101ALI20080414BHEP

Ipc: A61K 31/366 20060101ALI20080414BHEP

Ipc: A61K 31/28 20060101ALI20080414BHEP

Ipc: A61K 31/221 20060101ALI20080414BHEP

Ipc: A61K 31/198 20060101ALI20080414BHEP

Ipc: A61K 31/122 20060101ALI20080414BHEP

Ipc: A61K 31/05 20060101AFI20011106BHEP

17Q First examination report despatched

Effective date: 20080724

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090204